Comparative Pharmacology
Head-to-head clinical analysis: KANAMYCIN SULFATE versus TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANAMYCIN SULFATE versus TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
KANAMYCIN SULFATE vs TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
3-5 mg/kg/day IV divided every 8 hours or 5-7 mg/kg IV once daily for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
2-3 hours in patients with normal renal function; prolonged to 24-60 hours in anuria. Half-life is directly correlated with creatinine clearance.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Primarily renal (glomerular filtration) with >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal (<1%).
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic